Lunaphore is proud to announce that 2 new key team members have joined the company:
John Marotta, member of the Board of Directors:
John Marotta is the new Board member at Lunaphore and the President & CEO of Epredia, a PHC Group company focused on anatomical pathology. In addition to his role at Epredia, John is also a Corporate Officer for the PHC Group, and the Co-Domain Head for the Life Sciences and Diagnostics Domain. PHC Group is owned by KKR, as the largest shareholder.
Prior to joining Epredia, John’s most recent role was Senior Vice President of Supply Chain, Procurement, Real Estate, IT, Envista Business Systems and the LatAm Region. John has held senior level positions as a former Vice President and General Manager, President and CEO, Board member and other commercial and operations roles in companies such as Danaher, Cardinal Health and Emerge Medical. John began his career at Johnson & Johnson operating companies, Janssen Pharmaceutica and DePuy Synthes Orthopaedics, where he held various commercial roles.
Everton Robinson, VP Sales:
Everton Robinson is a highly experienced International Commercial Business Leader. He comes with a proven track record of success in building multi-disciplinary commercial operations infrastructure for innovative and disruptive technology providers in the life science and diagnostic industry. Everton has joined Lunaphore from NanoString Technologies, where he was Director of EMEA Life Science and Diagnostic Sales Operations and established the EMEA commercial organisation from the ground up to 50 FTEs across all functional areas. Prior to NanoString, Everton held various management positions at Illumina, ThermoFisher, Roche, Life Technologies, achieving career revenues from $5M to >$120M.
Everton gained his Doctorate in Molecular Genetics and Biochemistry from The University of Sussex, United Kingdom. He is also a qualified Advanced Executive Leadership coach.
Categories: Press Releases